FIG 5.

Sustained antiviral activity of GLP-26 in HBV-infected humanized mice by oral administration. Effect of entecavir (ETV) (0.3 mg/kg/day), GLP-26 (60 mg/kg/day) or the combination of ETV/ GLP-26 at the same doses on HBV DNA (A), HBsAg (B), HBeAg (C), and human albumin (D) in HBV-infected HUHEP mice. Treatment period is indicated in the gray shaded area followed by a rebound period. The lower limit of detection is shown as a thin dotted horizontal line in A and B. The thick dotted horizontal line shows the reference point of one for evaluating fold changes. Each full line represents the longitudinal results from an individual HBV-infected HUHEP mouse either untreated (black line), ETV-treated (green line), GLP-26-treated (blue line), or ETV/GLP-26-treated (red line).